



Sources
PhRMA, “Medicines in Development 2020 Update: Cell and Gene Therapy” (2020).
Beacon Targeted Therapies, “Our Highlights from CAR-TCR Europe 2020) (2020).
Intel shows a rise in cell and gene therapy development in the US, with China not far behind
Sources
PhRMA, “Medicines in Development 2020 Update: Cell and Gene Therapy” (2020).
Beacon Targeted Therapies, “Our Highlights from CAR-TCR Europe 2020) (2020).
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
False
False
November 7, 2014
0 min read
Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.
May 7, 2025
5 min read
Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.
April 1, 2025
3 min read
Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”
April 1, 2025
9 min read
Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.